Clirnet, a medical education solution provider has collaborated with multiple African Medical Associations. This aims to equip African healthcare professionals (HCPs) with seamless access to cutting-edge tools for enhancing medical learning.
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential...
Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These results were presented today in a late-breaking poster at the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in Washington, DC and form the basis for the Phase 3 program which is on track to start in 2024.
New Delhi, A drug called rilzabrutinib has generated promising safety and efficacy results in a recent international multi-centre phase 1-2 immune thrombocytopenia (ITP) trial, say researchers.
PARIS – April 14, 2022 - Positive results from the Phase 1/2 dose-finding study evaluating the safety, pharmacokinetics and clinical activity of rilzabrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrate treatment with rilzabrutinib led to a rapid and durable increase in platelet count and support an acceptable safety profile. Sanofi is investigating the safety and efficacy of twice daily rilzabrutinib (400 mg) for adults and adolescents with chronic ITP in the ongoing Phase 3 clinical study LUNA 3, initiated in April 2021.
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine Results published today in the New England Journal of...
Sanofi, in its third-quarter financials posted early Thursday morning, outlined a list of delays for a number of key assets as it dropped a biotech-partnered drug.nFirst up, those delays: We already knew its hemophilia hopeful fitusiran had problems after Sanofi started a new lower dose cohort in its phase 3 amid safety concerns, but now we know filing for the RNAi drug is not expected until 2024, after originally being penned in for next year.
When Sanofi acquired Principia Biopharma in 2020 for $3.68 billion, many analysts were skeptical, with Kerrisdale Capital calling Principia’s pipeline “worthless.” Not much has happened since to change their minds. On September 9, the company announced that its Phase III PEGASUS trial of rilzabrutinib for pemphigus flunked the study, failing to meet primary or key secondary endpoints. The drug was part of the Principia acquisition.
Sanofi`s BTK inhibitor flunks phase 3 autoimmune trial, delivering blow to $3.7B biotech bet
Sanofi has announced that its investigational oral Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib failed to meet the primary and secondary endpoints in a Phase III trial.